PHARMACEUTICAL COMPOSITIONS OF TIOPRONIN AND METHODS FOR PREPARING THEREOF
Pharmaceutical compositions are described herein, the compositions consisting essentially of anhydrous suspensions of therapeutically effective quantity of a pharmaceutically acceptable reducing agent capable of undergoing thiol-disulfide exchange with cystine to form a mixed disulfide (such as tiopronin). In some embodiments, the suspension also contains one or more urine alkanizing agent(s). Methods for fabricating the compositions and using them are also described.
1 . A pharmaceutical composition formulated as an anhydrous suspension comprising:
(a) a dispersed phase comprising a therapeutically effective quantity of a pharmaceutically acceptable reducing agent capable of undergoing thiol-disulfide exchange with cystine to form a mixed disulfide;
(b) at least one pharmaceutically acceptable surfactant or solubilizing and suspending agent; and
(c) an anhydrous dispersion medium,
wherein the dispersed phase is dispersed within the dispersion medium.
2 . The pharmaceutical composition of claim 1 , wherein the reducing agent is selected from the group consisting of tiopronin, D-penicilamine, or captopril, and any combination thereof.
3 . The pharmaceutical composition of claim 2 , wherein the reducing agent is tiopronin.
4 . The pharmaceutical composition of claim 3 , wherein the concentration of tiopronin in the composition is between about 1 mass % and about 5 mass %.
5 . The pharmaceutical composition of claim 1 , wherein the anhydrous dispersion medium comprises at least one vegetable oil or at least one medium chain triglyceride, or any combination thereof.
6 . The pharmaceutical composition of claim 5 , wherein the vegetable oil is selected from the group consisting of castor oil, soybean oil, coconut oil, avocado oil, olive oil, almond oil, and any combination thereof.
7 . The pharmaceutical composition of claim 5 , wherein the medium chain triglyceride is a triglyceride having at least two of the three fatty acid moieties that are derived from saturated open-chain acids having between 6 and 12 carbon atoms.
8 . The pharmaceutical composition of claim 7 , wherein the saturated open-chain acids are selected from the group consisting of caprylic acid and caproic acid.
9 . The pharmaceutical composition of claim 1 , wherein the surfactant or solubilizing and suspending agent is selected from the group consisting of non-ionic polyoxyethlene-polyoxypropylene block copolymers, a water-soluble derivative of cellulose, optionally partially cross-linked polyacrylates, polyoxyethylene sorbitan monolaurates, glyceryl distearate, triglycerol monooleate, glyceryl isostearate, polyoxyethylene sorbitan monopalmitates, polyoxyethylene sorbitan monostearates, and polyoxyethylene sorbitan monooleates.
10 . The pharmaceutical composition of claim 9 , wherein the non-ionic polyoxyethlene-polyoxypropylene block copolymer is poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol).
11 . The pharmaceutical composition of claim 9 , wherein the water-soluble derivative of cellulose is selected from the group consisting of carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, and hydroxypropyl cellulose.
12 . The pharmaceutical composition of claim 9 , wherein the solubilizing and suspending agent is polyoxyethylene (20) sorbitan monooleate.
13 . The pharmaceutical composition of claim 1 , further comprising at least one taste modifier selected from the group consisting of sweeteners, flavoring agents, and anesthetic agents.
14 . A method for treating, preventing or alleviating a disease, condition, syndrome, symptom, pathology, or malady in a mammalian subject in need of such treatment comprising orally administering to the subject the composition of claim 1 .
15 . The method of claim 14 , wherein the disease being prevented or treated is selected from the group consisting of kidney stone disease, cystinuria, bladder stone disease, ureter stone disease, rheumatoid arthritis and mucus formation in the airways, lungs, bronchi, and trachea of a patient.
16 . The method of claim 15 , wherein the disease being prevented or treated is cystinuria.
17 . The pharmaceutical composition of claim 1 , wherein the dispersed phase further comprises a therapeutically effective quantity of at least one urine alkanizing agent.
18 . The pharmaceutical composition of claim 17 , wherein the urine alkanizing agent is selected from the group consisting of alkali metal salts of citric acid, alkaline-earth metal salts of citric acid, and sodium bicarbonate.
19 . The pharmaceutical composition of claim 18 , wherein the alkali or alkaline-earth metal salts of citric acid are selected from the group consisting of potassium citrate, sodium citrate, and magnesium citrate.
20 . The pharmaceutical composition of claim 17 , wherein the concentration of the urine alkanizing agent in the composition is between about 2 mass % and about 20 mass %.
21 . The pharmaceutical composition of claim 17 , wherein the formulation is adapted for oral administration.